<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Conduit Pharmaceuticals Inc. — News on 6ix</title>
    <link>https://6ix.com/company/conduit-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Conduit Pharmaceuticals Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 16 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/conduit-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <item>
      <title>CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-expands-multi-pathway-value-creation-strategy-across-pharma-ip-and-ai-driven-discovery</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-expands-multi-pathway-value-creation-strategy-across-pharma-ip-and-ai-driven-discovery</guid>
      <pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today provides a</description>
    </item>
    <item>
      <title>CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-expands-tapinarof-intellectual-property-portfolio-with-two-new-patent-filings</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-expands-tapinarof-intellectual-property-portfolio-with-two-new-patent-filings</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the</description>
    </item>
    <item>
      <title>CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-identifies-rare-disease-opportunities-through-sarborg-signature-analysis-advancing-out-licensing-strategy</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-identifies-rare-disease-opportunities-through-sarborg-signature-analysis-advancing-out-licensing-strategy</guid>
      <pubDate>Mon, 23 Mar 2026 12:30:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that it has completed initial signature mapping of its asset portfolio against Sarborg Limited’s recently curated rare disease database, identifying multiple high-potential opportunities across a range of rare and underserved indications. The analysis, conducted using Sarborg’s proprietary AI Signature Agent platform, evaluated CDT’s portfolio of</description>
    </item>
    <item>
      <title>CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-stockholders-approve-all-proposals-at-special-meeting-positioning-the-company-for-next-phase-of-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-stockholders-approve-all-proposals-at-special-meeting-positioning-the-company-for-next-phase-of-growth</guid>
      <pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that all</description>
    </item>
    <item>
      <title>CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-notes-sarborg-filing-of-us-provisional-patent-application-for-ai-signature-agent-1</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-notes-sarborg-filing-of-us-provisional-patent-application-for-ai-signature-agent-1</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the</description>
    </item>
    <item>
      <title>CDT Positions for Transformational Growth</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-positions-for-transformational-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-positions-for-transformational-growth</guid>
      <pubDate>Wed, 04 Mar 2026 13:30:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 04, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) advances multiple initiatives designed to enhance shareholder value and expand its strategic footprint. The Company continues to actively develop and expand its pharmaceutical asset portfolio, including solid-form and cocrystal development programs, alongside its licensed clinical assets AZD1656, AZD5658 and AZD5904 under its agreement with AstraZeneca. CDT remain</description>
    </item>
    <item>
      <title>CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-notes-sarborg-expansion-into-bacteria-and-agrochemicals</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-notes-sarborg-expansion-into-bacteria-and-agrochemicals</guid>
      <pubDate>Tue, 24 Feb 2026 13:30:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 24, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement issued this morning by Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform beyond pharmaceuticals into bacteria and agrochemicals. CDT holds a significant 20% equity stake in Sarborg and views this expansion as a meaningful strategic development in the continued evolution of Sarborg’s cross-industry s</description>
    </item>
    <item>
      <title>CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-acquires-strategic-stake-in-sarborg-to-transform-its-ai-driven-asset-strategy</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-acquires-strategic-stake-in-sarborg-to-transform-its-ai-driven-asset-strategy</guid>
      <pubDate>Fri, 20 Feb 2026 13:30:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited (“Sarborg”), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT’s clini</description>
    </item>
    <item>
      <title>CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-engages-njs-foresight-bio-advisory-to-support-solid-form-out-licensing-strategy</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-engages-njs-foresight-bio-advisory-to-support-solid-form-out-licensing-strategy</guid>
      <pubDate>Fri, 02 Jan 2026 05:00:00 GMT</pubDate>
      <description>Engagement reinforces CDT’s strategy to unlock value from its solid-form asset portfolio NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 02, 2026 (GLOBE</description>
    </item>
    <item>
      <title>CDT Equity Inc. Announces Reverse Stock Split</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-inc-announces-reverse-120000410</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-inc-announces-reverse-120000410</guid>
      <pubDate>Thu, 09 Oct 2025 12:00:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-8 reverse stock split of the Company’s common stock. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios, at the Company’s Special Meeting of Stockholders held on May 5, 2025. The directors expect</description>
    </item>
    <item>
      <title>CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-identifies-biological-target-123000923</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/cdt-equity-identifies-biological-target-123000923</guid>
      <pubDate>Tue, 26 Aug 2025 12:30:00 GMT</pubDate>
      <description>Using AI, CDT Equity Inc. identifies a novel therapeutic indication for its lead programmes, supported by successful pre-clinical trial dataNAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1656 (and its derivatives), following positive data from pre-clinical studies. This affirms</description>
    </item>
    <item>
      <title>Conduit to Change Name to CDT Equity Inc.</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-change-name-cdt-equity-123000903</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-change-name-cdt-equity-123000903</guid>
      <pubDate>Tue, 05 Aug 2025 12:30:00 GMT</pubDate>
      <description>Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation, strategic partnerships and out-licensing NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (&quot;Conduit&quot; or the “Company”) today announce that it intends to change its name to CDT Equity Inc. (“CDT”) reflecting the evolution of its strategy as a data-dri</description>
    </item>
    <item>
      <title>Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-files-new-patents-following-ai-driven-combination-discoveries</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-files-new-patents-following-ai-driven-combination-discoveries</guid>
      <pubDate>Mon, 07 Jul 2025 04:00:00 GMT</pubDate>
      <description>Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from</description>
    </item>
    <item>
      <title>Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-enters-joint-development-123000327</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-enters-joint-development-123000327</guid>
      <pubDate>Wed, 04 Jun 2025 12:30:00 GMT</pubDate>
      <description>Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health marketEvaluation of AZD5658 expands Conduit’s glucokinase activator platform into novel veterinary applications, complementing AZD1656 developmentCost-efficient approach enhances Conduit’s pipeline while preserving full ownership of intellectual property and data, maximizing shareholder valu</description>
    </item>
    <item>
      <title>Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-inc-listing-nasdaq-123000326</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-inc-listing-nasdaq-123000326</guid>
      <pubDate>Thu, 22 May 2025 12:30:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that th</description>
    </item>
    <item>
      <title>Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-inc-regains-nasdaq-123000043</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-inc-regains-nasdaq-123000043</guid>
      <pubDate>Wed, 21 May 2025 12:30:00 GMT</pubDate>
      <description>Conduit regains compliance with Bid Price and Equity RequirementsCDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announced that the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that t</description>
    </item>
    <item>
      <title>Conduit Pharmaceuticals Inc. Announces Reverse Stock Split</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-inc-announces-reverse-123000360</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-inc-announces-reverse-123000360</guid>
      <pubDate>Fri, 16 May 2025 12:30:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-15 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders hel</description>
    </item>
    <item>
      <title>Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-receives-further-patent-123000293</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-receives-further-patent-123000293</guid>
      <pubDate>Fri, 09 May 2025 12:30:00 GMT</pubDate>
      <description>Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 09, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (&quot;Conduit Pharmaceuticals&quot;, &quot;Conduit&quot; or the “Company”) today announces that the Korean Intellectual Property Office (KIPO) ha</description>
    </item>
    <item>
      <title>Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-files-composition-matter-123000547</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-files-composition-matter-123000547</guid>
      <pubDate>Thu, 08 May 2025 12:30:00 GMT</pubDate>
      <description>New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit’s pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases. NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 08, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (&quot;Conduit Pharmaceuticals&quot;, &quot;Conduit&quot; or the “Company”) today announces the filing of a new composition of matter patent cover</description>
    </item>
    <item>
      <title>Conduit Pharmaceuticals Announces Leadership Changes</title>
      <link>https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-announces-leadership-changes-123000925</link>
      <guid isPermaLink="true">https://6ix.com/company/conduit-pharmaceuticals-inc/news/conduit-pharmaceuticals-announces-leadership-changes-123000925</guid>
      <pubDate>Wed, 16 Apr 2025 12:30:00 GMT</pubDate>
      <description>NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (&quot;Conduit Pharmaceuticals&quot; or &quot;Conduit&quot; or the &quot;Company&quot;) today announced key leadership changes to support the company’s next phase of growth and execution. Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will succeed Dr. David Tapolczay, who is stepping down as CEO and as a member of the B</description>
    </item>
  </channel>
</rss>